Rett Syndrome Drug Could Propel Newron To Next Level In 2018
Executive Summary
Newron Pharmaceuticals will file its investigational drug sarizotan in 2018 for respiratory issues in patients with Rett syndrome, setting it up to be the first therapy specifically indicated for this rare genetic disease. CEO Stefan Weber spoke to Scrip about Newron's commercial strategy for sarizotan and broader prospects for the evolving drug developer.
You may also be interested in...
Newron Seeks New Assets To Grow Pipeline
Newron has raised $27m via a private placement to fund late-stage development of its novel schizophrenia drug and to license new assets that will bulk up its limited clinical pipeline.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.